Safety of amphotericin B colloidal dispersion

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 16, Issue 1, 1997, Pages 74-80

  Herbrecht, R ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; BILIRUBIN; CREATININE;

ADOLESCENT; AGED; CENTRAL NERVOUS SYSTEM DEPRESSION; CHILD; CHILL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; FEMALE; FEVER; HUMAN; HYPERTENSION; HYPOTENSION; HYPOXIA; KIDNEY DISEASE; KIDNEY FAILURE; LIVER FUNCTION; LIVER LEVEL; MAJOR CLINICAL STUDY; MALE; MYCOSIS; NEPHROTOXICITY; NEWBORN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TACHYCARDIA; THROMBOCYTOPENIA;

AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; COLLOIDS; CREATININE; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOCOMPROMISED HOST; KIDNEY; MYCOSES;

EID: 0031045740     PISSN: 09349723     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01575124     Document Type: Conference Paper

References (17)

1. Sepkowitz KA, Armstrong D: Treatment of opportunist infections in AIDS. Lancet 1995, 346: 588-589.
2. Emminger W, Lang HR, Emminger-Schidmeier W, Peters C, Gadner H: Amphotericin B serum levels in paediatric bone marrow transplant recipients. Bone Marrow Transplant 1991, 7: 95-99.
3. Schell RE, Tran NV, Bramhall JS: Amphotericin B-induced changes in renal membrane permeation: a model of nephrotoxicity. Biochemical and Biophysical Research Communications 1989, 159: 1165-1170.
4. Sabra R, Branch RA: Amphotericin B nephrotoxicity. Drug Safety 1990, 5: 94-108.
5. Heyman SN, Clark BA, Kaiser N, Epstein FH, Spokes K, Rosen S, Brezis M: In vivo and in vitro studies on the effect of amphotericin B on endothelin release. Journal of Antimicrobial Chemotherapy 1992, 29: 69-77.
6. Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GG, Bowles CA, Karan GH, Espinel-Ingroff A: Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. American Journal of Medicine 1987, 83: 236-242.
7. Clements JS, Peacock JE: Amphotericin revisited: reas-sessment of toxicity. American Journal of Medicine 1990, 88 (5N): 22N-27N.
8. Reusser P, Ganbertoglio JG, Lilleby K, Meyers JD: Phase I-II trial of foscarnet for prevention of cytomegalo-virus infection in autologous and allogenic marrow transplant recipients. Journal of Infectious Diseases 1992, 166: 473-479.
9. Sands M, Brown RB: Interactions of cyclosporine with antimicrobial agents. Reviews of Infectious Diseases 1989, 11: 691-697.
10. Mufson D, Guo LSS, Fielding RM: Amphotericin B-cholesteryl sulfate complex: stability and tissue distribution of a novel dosage form. Proceedings of the International Symposium for Controlled Release of Bioactive Materials 1990, 17: 81-82.
11. Fielding RM, Smith PC, Wang LH, Porter J, Guo LSS: Comparative pharmacokinetics of Amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrobial Agents and Chemotherapy 1991, 35: 1208-1213.
12. Medoff G, Koboyashi GS: Strategies in the treatment of systemic fungal infections. New England Journal of Medicine 1980, 302: 145-148.
13. Butler WT, Bennett JE, Ailing DW, Westlake PT, Utz JR Hill GJ: Nephrotoxicity of amphotericin B, early and late effects in 81 patients. Annals of Internal Medicine 1964, 61: 175-187.
14. Proffitt RT, Satorius A, Chang SM, Sullivan L, Adler-Moore JP: Pharmacology and toxicology of a liposomal formulation of amphotericin B (Ambisome) in rodents. Journal of Antimicrobial Chemotherapy 1991, 28 Supplement B: 49-61.
15. Khoo SH, Bond J, Denning DW: Administering ampho-tericin B - a practical approach. Journal of Antimicrobial Chemotherapy 1994, 38: 203-213.
16. Rex JH, Bennett JE, Sugar AM, Pappas PG, Van Der Hoerst CM, Edwards JE, Washburn RG, Scheid WR, Karchmer AW, Dine AP, Levenstein MJ, Webb CD: A randomised trial comparing fluconazole with amphotericin B for the treatment of candidaemia in patients without neutropenia. New England Journal of Medicine 1994, 331: 1325-1331.
17. Oppenheim B, Herbrecht R, Kusne S: The safety and efficacy of amphotericin B colloidal dispersion in the treatment of invasive mycoses. Clinical Infectious Diseases 1995, 21: 1145-1153.